Cost Insights: Breaking Down Pharming Group N.V. and Mesoblast Limited's Expenses

Biotech Cost Trends: Pharming vs. Mesoblast

__timestamp	Mesoblast Limited	Pharming Group N.V.
Wednesday, January 1, 2014	25434000	4167274
Thursday, January 1, 2015	23783000	5247851
Friday, January 1, 2016	29763000	4925118
Sunday, January 1, 2017	12065000	14930297
Monday, January 1, 2018	5508000	25371768
Tuesday, January 1, 2019	75173000	23921274
Wednesday, January 1, 2020	81497000	25338236
Friday, January 1, 2021	85731000	20182966
Saturday, January 1, 2022	63572000	17562000
Sunday, January 1, 2023	54922000	25212000
Monday, January 1, 2024	41070000

Unlocking the unknown

Unveiling Cost Dynamics in Biotech: Pharming Group N.V. vs. Mesoblast Limited

In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Pharming Group N.V. and Mesoblast Limited from 2014 to 2023. Over this decade, Mesoblast Limited's cost of revenue peaked in 2021, reaching approximately 86 million, a staggering 70% increase from its 2014 figures. In contrast, Pharming Group N.V. saw a more stable trajectory, with costs peaking in 2018 at around 25 million, marking a 500% rise from 2014. Notably, 2024 data for Pharming Group N.V. remains unavailable, highlighting potential gaps in reporting. These insights underscore the dynamic nature of cost management in biotech, where strategic financial planning can significantly impact a company's competitive edge.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025